TP53 and neoplasm: Importantly, the emergence of resistance to tozasertib was not associated with the p53 status of the tumor cell lines (e.g., U87 was p53 wild‐type, whereas LNZ308 was p53 deleted) and cell cycle analysis showed a paucity of cells with 4N or greater DNA content, a sharp contrast to short‐term treated cells.